Informações de Bristol-Myers Squibb Co

Mais detalhes de Bristol-Myers Squibb Co Empresa

Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.



Código da empresaBMY

Nome da EmpresaBristol-Myers Squibb Co

Data de listagemMar 17, 1980

CEODr. Christopher S. (Chris) Boerner, Ph.D.

Número de funcionários34100

Tipo de títulosOrdinary Share

Fim do ano fiscalMar 17

EndereçoRoute 206 And Province Line Road

CidadePRINCETON

Bolsa de valoresNYSE Consolidated

PaísUnited States of America

Código postal08543

Telefone16092524621

Sitehttps://www.bms.com

Código da empresaBMY

Data de listagemMar 17, 1980

CEODr. Christopher S. (Chris) Boerner, Ph.D.

Executivos da empresa Bristol-Myers Squibb Co



Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Christopher S. (Chris) Boerner, Ph.D.

Chairman of the Board, Chief Executive Officer

62.72K

-50.00%

Ms. Karin Shanahan

Executive Vice President, Global Product Development & Supply, Member of the Leadership Team

16.70K

+10.70%

Dr. Julia A. Haller, M.D.

Independent Director

13.62K

--

Mr. Adam Lenkowsky

Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team

12.44K

+87.05%

Ms. Cari Gallman

Executive Vice President, General Counsel and Chief Policy Officer

11.07K

+25.18%

Dr. Manuel Hidalgo Medina, M.D., Ph.D.

Independent Director

--

Mr. Derica W. Rice

Independent Director

--

Ms. Lynelle Hoch

President, Cell Therapy Organization, Member of the Leadership Team

--

Dr. Deepak L. Bhatt, M.D.

Independent Director

--

Mr. Phil Holzer

Senior Vice President, Controller

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Christopher S. (Chris) Boerner, Ph.D.

Chairman of the Board, Chief Executive Officer

62.72K

-50.00%

Ms. Karin Shanahan

Executive Vice President, Global Product Development & Supply, Member of the Leadership Team

16.70K

+10.70%

Dr. Julia A. Haller, M.D.

Independent Director

13.62K

--

Mr. Adam Lenkowsky

Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team

12.44K

+87.05%

Ms. Cari Gallman

Executive Vice President, General Counsel and Chief Policy Officer

11.07K

+25.18%

Dr. Manuel Hidalgo Medina, M.D., Ph.D.

Independent Director

--

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de out

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Por EmpresaUSD

Nome

Receita

Proporção

Eliquis

3.68B

30.00%

Opdivo

2.59B

21.09%

Orencia

963.00M

7.85%

Revlimid

838.00M

6.83%

Yervoy

728.00M

5.93%

Outro

3.47B

28.29%

Por RegiãoUSD

Nome

Receita

Proporção

United States

8.52B

69.44%

International

3.48B

28.37%

other

270.00M

2.20%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Eliquis

3.68B

30.00%

Opdivo

2.59B

21.09%

Orencia

963.00M

7.85%

Revlimid

838.00M

6.83%

Yervoy

728.00M

5.93%

Outro

3.47B

28.29%

Distribuição de ações

Atualizado em: ter, 4 de nov

Investidores

Tipos de investidores

Investidores

Proporção

The Vanguard Group, Inc.

9.53%

BlackRock Institutional Trust Company, N.A.

4.88%

State Street Investment Management (US)

4.65%

Charles Schwab Investment Management, Inc.

3.48%

JP Morgan Asset Management

3.31%

Outro

74.15%

Investidores

Proporção

The Vanguard Group, Inc.

9.53%

BlackRock Institutional Trust Company, N.A.

4.88%

State Street Investment Management (US)

4.65%

Charles Schwab Investment Management, Inc.

3.48%

JP Morgan Asset Management

3.31%

Outro

74.15%

Tipos de investidores

Investidores

Proporção

Investment Advisor

46.45%

Investment Advisor/Hedge Fund

25.61%

Research Firm

2.95%

Pension Fund

2.59%

Bank and Trust

2.29%

Sovereign Wealth Fund

1.75%

Hedge Fund

1.14%

Insurance Company

0.16%

Family Office

0.06%

Outro

16.99%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

4101

1.70B

83.42%

+9.48M

2025Q2

4180

1.70B

83.46%

+31.40M

2025Q1

4287

1.68B

82.63%

+10.66M

2024Q4

4261

1.65B

81.14%

+17.04M

2024Q3

4116

1.60B

78.69%

-22.73M

2024Q2

4105

1.59B

78.35%

-83.12M

2024Q1

4118

1.64B

80.97%

+13.32M

2023Q4

4115

1.60B

78.83%

-46.39M

2023Q3

4042

1.63B

77.83%

-55.50M

2023Q2

4082

1.66B

78.77%

-34.93M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

The Vanguard Group, Inc.

193.94M

9.53%

+3.47M

+1.82%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

99.37M

4.88%

+1.60M

+1.64%

Jun 30, 2025

State Street Investment Management (US)

94.74M

4.65%

-94.48K

-0.10%

Jun 30, 2025

Charles Schwab Investment Management, Inc.

70.80M

3.48%

+10.20M

+16.82%

Jun 30, 2025

JP Morgan Asset Management

67.41M

3.31%

-2.47M

-3.54%

Jun 30, 2025

Capital International Investors

66.16M

3.25%

-303.34K

-0.46%

Jun 30, 2025

Geode Capital Management, L.L.C.

46.18M

2.27%

+723.46K

+1.59%

Jun 30, 2025

Norges Bank Investment Management (NBIM)

33.57M

1.65%

-1.60M

-4.55%

Jun 30, 2025

Columbia Threadneedle Investments (US)

29.38M

1.44%

+350.53K

+1.21%

Jun 30, 2025

Wellington Management Company, LLP

25.82M

1.27%

+2.09M

+8.83%

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: sáb, 1 de nov

Nome

Proporção

LSV Disciplined Value ETF

83.29%

First Trust NASDAQ Pharmaceuticals ETF

7.02%

VanEck Morningstar Wide Moat Value ETF

4.23%

iShares U.S. Pharmaceuticals ETF

4.22%

VanEck Pharmaceutical ETF

3.69%

Schwab U.S. Dividend Equity ETF

3.66%

Franklin US Dividend Booster Index ETF

3.46%

First Trust Morningstar Dividend Leaders Index Fund

3.11%

Brookstone Value Stock ETF

3.1%

Tema Oncology ETF

3.07%

Ver Mais

LSV Disciplined Value ETF

Proporção83.29%

First Trust NASDAQ Pharmaceuticals ETF

Proporção7.02%

VanEck Morningstar Wide Moat Value ETF

Proporção4.23%

iShares U.S. Pharmaceuticals ETF

Proporção4.22%

VanEck Pharmaceutical ETF

Proporção3.69%

Schwab U.S. Dividend Equity ETF

Proporção3.66%

Franklin US Dividend Booster Index ETF

Proporção3.46%

First Trust Morningstar Dividend Leaders Index Fund

Proporção3.11%

Brookstone Value Stock ETF

Proporção3.1%

Tema Oncology ETF

Proporção3.07%

Dividendo



Um total de 22.71B USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Dec 11, 2024

BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Feb 03, 2025 going ex on Jan 03, 2025 with reinvestment option

Jan 03, 2025

Feb 03, 2025

Jan 03, 2025

Sep 10, 2024

BMY.NB Final Cash Dividend of gross USD 0.6 paid on Nov 01, 2024 going ex on Oct 04, 2024 with reinvestment option

Oct 04, 2024

Nov 01, 2024

Oct 04, 2024

Jun 18, 2024

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Aug 01, 2024 going ex on Jul 05, 2024 with reinvestment option

Jul 05, 2024

Aug 01, 2024

Jul 05, 2024

Mar 01, 2024

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on May 01, 2024 going ex on Apr 04, 2024 with reinvestment option

Apr 05, 2024

May 01, 2024

Apr 04, 2024

Dec 06, 2023

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Feb 01, 2024 going ex on Jan 04, 2024 with reinvestment option

Jan 05, 2024

Feb 01, 2024

Jan 04, 2024

Sep 20, 2023

BMY.NB Final Cash Dividend of gross USD 0.57 paid on Nov 01, 2023 going ex on Oct 05, 2023

Oct 06, 2023

Nov 01, 2023

Oct 05, 2023

Jun 14, 2023

BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Aug 01, 2023 going ex on Jul 06, 2023 with reinvestment option

Jul 07, 2023

Aug 01, 2023

Jul 06, 2023

Mar 03, 2023

BMY.NB Interim Cash Dividend of gross USD 0.57 paid on May 01, 2023 going ex on Apr 06, 2023

Apr 10, 2023

May 01, 2023

Apr 06, 2023

Dec 08, 2022

BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Feb 01, 2023 going ex on Jan 05, 2023

Jan 06, 2023

Feb 01, 2023

Jan 05, 2023

Sep 14, 2022

BMY.NB Final Cash Dividend of gross USD 0.54 paid on Nov 01, 2022 going ex on Oct 06, 2022

Oct 07, 2022

Nov 01, 2022

Oct 06, 2022

Ver Mais

Desdobramento de ações



Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados